Lomerizine

Lomerizine
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H30F2N2O3
Molar mass468.545 g·mol−1
3D model (JSmol)
  • COC1=C(C(=C(C=C1)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC)OC
  • InChI=1S/C27H30F2N2O3/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20/h4-13,25H,14-18H2,1-3H3 ☒N
  • Key:JQSAYKKFZOSZGJ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Lomerizine (INN) (also known as KB-2796) is a diphenylpiperazine class L-type and T-type calcium channel blocker.[1] This drug is currently used clinically for the treatment of migraines, while also being used experimentally for the treatment of glaucoma and optic nerve injury.

  1. ^ Selt M, Bartlett CA, Harvey AR, Dunlop SA, Fitzgerald M (March 2010). "Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine". Brain Research Bulletin. 81 (4–5): 467–471. doi:10.1016/j.brainresbull.2009.11.004. PMID 19913075. S2CID 39918828.